NeuroOne Medical Technologies (NMTC, Financial) has submitted its 510(k) application for FDA approval ahead of schedule, aiming to introduce its OneRF Ablation System for treating trigeminal neuralgia. This chronic pain condition impacts approximately 100,000 individuals in the United States, causing intense facial pain due to issues with the trigeminal nerve, the primary sensory nerve in the face.
The OneRF Trigeminal Nerve Ablation System employs a minimally invasive procedure that utilizes radiofrequency energy to target and eliminate abnormal tissue. This approach aims to alleviate the severe, persistent facial pain associated with trigeminal neuralgia, offering an alternative to current treatments that range from medication to invasive surgical methods such as microvascular decompression and radiosurgery.
Key innovations of NeuroOne's system include a multi-contact probe that integrates pain location mapping, stimulation, and ablation functions, all with a single electrode. The system also features temperature-controlled ablation, enhancing patient safety. These capabilities mirror those of the FDA-cleared OneRF sEEG Ablation System, potentially offering advantages such as reduced procedural time, increased patient comfort, and improved safety outcomes.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for NeuroOne Medical Technologies Corp (NMTC, Financial) is $3.15 with a high estimate of $3.15 and a low estimate of $3.15. The average target implies an upside of 488.35% from the current price of $0.54. More detailed estimate data can be found on the NeuroOne Medical Technologies Corp (NMTC) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, NeuroOne Medical Technologies Corp's (NMTC, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for NeuroOne Medical Technologies Corp (NMTC, Financial) in one year is $4.68, suggesting a upside of 774.11% from the current price of $0.5354. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the NeuroOne Medical Technologies Corp (NMTC) Summary page.
